市場調查報告書

膽道閉鎖的市場規模,分析及流行病學:至2030年的預測

Biliary Atresia - Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955307
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
膽道閉鎖的市場規模,分析及流行病學:至2030年的預測 Biliary Atresia - Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 2020年08月01日內容資訊: 英文 130 Pages
簡介

主要7個國家(美國,德國,西班牙,義大利,法國,英國,日本)的膽道閉鎖的市場規模,2017年是290萬美金。膽道閉鎖的管理和診斷不如過去10年大幅度發展,不過,由於時機與潛在病因的闡明中最近的進步,10年之間預期帶來早期診斷與新的治療方法。

本報告提供主要7個國家(美國,德國,西班牙,義大利,法國,英國,日本)的膽道閉鎖的市場規模相關調查調查,市場洞察,預測,流行病學,成長及阻礙因素,機會等資訊。

目錄

第1章 主要洞察

第2章 膽道閉鎖:市場概況一覽

  • 市場佔有率:2017年的膽道閉鎖的分佈
  • 市場佔有率:2030年的膽道閉鎖的分佈

第3章 摘要整理

第4章 組織

第5章 疾病概要:膽道閉鎖

  • 簡介
  • 徵兆與症狀
  • 膽道閉鎖的分類
  • 解剖學的形態
  • 膽道閉鎖臨床表現型
  • 分類
  • 病因
  • 診斷
  • 鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 膽道閉鎖的總患者數主要7個國家
  • 美國
  • 前提條件與根據
  • 美國膽道閉鎖的總有症數
  • 美國膽道閉鎖的各類型的病例
  • 美國膽道閉鎖的性別的病例
  • 歐洲5個國家
  • 前提條件與根據
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 治療和管理

  • 外科的管理
  • 肝臟移植
  • 醫療管理

第8章 潛在的需求

第9章 新治療方法

  • 主要的要點
  • Odevixibat:Albireo
    • 藥物的說明
    • 其他發展活動
    • 臨床開發
    • 臨床實驗資訊
    • 安全性和有效性
    • 產品的簡介
  • 奧貝膽酸
    • 臨床試驗資訊

第10章 膽道閉鎖:7個主要市場分析

  • 主要調查結果
  • 主要7個國家的膽道閉鎖的市場規模
  • 市場預測
  • 美國的市場規模
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本市場規模

第11章 市場成長要素

第12章 市場障礙

第13章 SWOT分析

第14章 案例研究

  • 伴隨了胰膽管連接不良的膽道閉鎖
  • 案例研究:膽道閉鎖:病例報告
  • 案例研究:遲發性膽道閉鎖的診斷的臨床性及病理學的課題:4個案例研究

第15章 KOL的見解

第16章 參考文件

第17章 附錄

第18章 報告的調查手法

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0994

DelveInsight's 'Biliary Atresia- Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Biliary Atresia market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Biliary Atresia market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Biliary Atresia symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Biliary Atresia Disease Understanding and Treatment Algorithm

Biliary Atresia Overview

Biliary Atresia is a neonatal liver disease characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree along with fibrosis and inflammation of the liver parenchyma. The etiology and pathogenesis of BA remain unknown. Recent studies are examining potential pathogenetic mechanisms of BA, including genetic susceptibility, the involvement of the immune system, and environmental insults such as viruses and toxins. It is possible that there is not a single etiological agent but rather a large group of injurious insults that might result in a final common pathway of extrahepatic bile duct obstruction and liver fibrosis.

The symptoms of Biliary Atresia usually appear by the age of 2-6 weeks. They include a yellowish coloration of the skin and whites of the eyes (jaundice), abnormally pale stools, and dark urine. Infants may also have swollen (distended) stomach and/or abnormal enlargement of the liver (hepatomegaly). The pathway from clinical suspicion to establishing the diagnosis of Biliary Atresia in a child with jaundice is a daunting task-however, investigations available help point the correct diagnosis in a reasonable time frame.Imaging by sonography has identified several parameters which can be of help in the diagnostic workup. Comparison of sonography with imaging by nuclear medicine can bring out significant differences and also avoid inappropriate imaging. The battery of biochemical tests, available currently, enable a better understanding of the line-up of investigations in a given child with neonatal cholestasis. Untreated, Biliary Atresia remains a fatal condition of the newborn. Most present within 4-6 weeks of conjugated jaundice and acholic stools, and although still a challenging diagnosis to make, therein lies the opportunity of changing the course of this otherwise inexorable disease.

Biliary Atresia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Biliary Atresia market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Biliary Atresia market report gives a thorough understanding of Biliary Atresia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Biliary Atresia treatment algorithms and treatment guidelines for Biliary Atresia in the US, Europe, and Japan.

Biliary Atresia Epidemiology

The Biliary Atresia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology segmented as the Total Incident Cases of Biliary Atresia, Gender-specific Cases of Biliary Atresia, and Type-specific Cases of Biliary Atresia. The report includes the Incident scenario of Biliary Atresia in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Biliary Atresia Epidemiology

The epidemiology segment also provides the Biliary Atresia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Biliary Atresiain 7MM countries was estimated to be 613 cases in 2017.

Biliary Atresia Drug Chapters

The drug chapter segment of the Biliary Atresia report encloses the detailed analysis of Biliary Atresia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Biliary Atresia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no FDA approved therapy for treatment of Biliary Atresia. The therapeutic market size of Biliary Atresia in the US is mainly accounted for off label treatment options including choleretics such as ursodeoxycholic acid (UDCA), anti-inflammatory medications, steroids, nutritional rehabilitation, and fat-soluble vitamin supplementation

Products detail in the report…

Biliary Atresia Emerging Drugs

Odevixibat (Albireo) a potent and selective inhibitor of the ileal bile acid transporter (IBAT), also known as apical sodium-dependent bile acid transporter (ASBT), acts locally in the gut, and has minimal systemic exposure at the therapeutic dose. IBAT initiates the transport of bile acids, which flow through the portal vein back to the liver in a process known as enterohepatic circulation. Approximately 95% of bile acids are recirculated via the IBAT to the liver. Accordingly, a product capable of inhibiting the IBAT could lead to a reduction in bile acids returning to the liver and may represent a promising approach for treating cholestatic liver diseases. Therefore, Odevixibat works by decreasing the reabsorption of bile acids from the small intestine to the liver, which reduces the toxic levels of bile acids during the progression of the disease. It exhibits therapeutic intervention by checking the transport of bile acids.

The company presented the data from phase II trial in pediatric cholestasis that supports the potential of odevixibat in Biliary Atresia and Alagille syndrome at the European Association for the Study of the Liver (EASL) annual conference.

Currently, the company is conducting the phase III trial for the treatment of Biliary Atresia. Both FDA and EMA also have granted Orphan Drug Designation to Odevixibat for the treatment of Biliary Atresia.

Products detail in the report…

Biliary Atresia Market Outlook

The Biliary Atresia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Biliary Atresia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Biliary Atresia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Biliary Atresia market in 7MM is expected to change in the study period 2017-2030.

The management and diagnosis of BA have not advanced significantly in the past decade, but given recent advances in understanding the timing and potential pathogenesis of BA, it is hopeful that the next decade will bring early diagnostics and novel therapeutics.

Key Findings

This section includes a glimpse of the Biliary Atresia market in 7MM. The market size of Biliary Atresia in the seven major markets was found to be USD 2.9 million, in 2017.

The United States Market Outlook

This section provides the total Biliary Atresia market size and market size by therapies in the United States.

The United States accounts for the highest market size of Biliary Atresia in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

The treatment of BA is surgical and currently recommended as a sequence of, eventually, two interventions. During the first months of life, a Hepatoportoenterostomy (a "Kasai," modifications) should be performed, to restore the biliary flow to the intestine and lessen further damage to the liver.

If this fails or the disease progresses towards biliary cirrhosis and life-threatening complications, then liver transplantation is indicated, for which Biliary Atresia represents the most frequent pediatric indication.

The indications for liver transplantation depend on the success of the Kasai portoenterostomy and the rate of development of complications. In those infants in whom bile drainage is not achieved, transplantation is usually indicated within the first year or life. In children with a successful Kasai portoenterostomy, liver transplantation should be considered if there is persistent or progressive cholestasis, development of cirrhosis with hepatic dysfunction, or development of portal hypertension with ascites and variceal bleeding unresponsive to endoscopic management.

In the Postoperative Management, medical care following HPE consists of interventions such as Choleretics and possible use of anti-inflammatory medications, Nutritional rehabilitation, Fat-soluble vitamin supplementation, Prevention of cholangitis, management of portal hypertension and its sequel.

Despite these measures, many infants and children with BA require supplemental feeding by nasogastric tube because they are unable to take enough energy by mouth to meet their increased nutritional needs.

Deficiencies of fat-soluble vitamins are common in patients with BA. Vitamin deficiencies occur despite recommended supplementation and are particularly common among patients with residual cholestasis after Kasai HPE. Therefore, vitamin levels should be monitored frequently. Infants with BA and prolonged jaundice may especially be deficient in vitamin K.

EU-5 Countries: Market Outlook

The total Biliary Atresia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

The treatment regime for most children with diagnosed BA include surgery, whereby an attempt is made to preserve the infant's liver. Kasai operation is performed which essentially excises all extrahepatic biliary remnants leaving a transected portal plate, followed by biliary reconstruction using a Roux loop onto that plate as a Hepatoportoenterostomy. However, liver transplantation is indicated in BA in three different clinical settings. It may be necessary for infants who have a delayed diagnosis of BA and hence have not been subjected to a KPE. These children usually present within 1 year of age with intense jaundice, synthetic liver dysfunction, and failure to thrive. The second group of children is those who undergo a KPE but do not overcome synthetic failure. These children need transplantation in the first 2 years of life. The indications in this group include jaundice, portal hypertension, and failure to thrive. The third group of children (or adults) is those who have successfully cleared jaundice after the KPE but have recurrent cholangitis, portal hypertension, or hepatopulmonary syndrome.

Furthermore, surgical treatment essentially involves post operative management regime which mainly consists of antibiotics, ursodeoxycholic acid to encourage bile flow, fat-soluble vitamin supplementation, and nutritional support.

Japan Market Outlook

The total Biliary Atresiamarket size and market size by therapies in Japan are also mentioned.

Biliary Atresia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Biliary Atresia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Biliary Atresia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Biliary Atresia key players involved in developing targeted therapeutics.

Major players include Intercept Pharmaceuticals, Albireo etc. which are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Biliary Atresia emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Biliary Atresiadomain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Biliary Atresia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Biliary Atresia Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Biliary Atresia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Biliary Atresia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Atresia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Biliary Atresia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Atresia market

Report Highlights:

  • In the coming years, Biliary Atresia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Atresia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Biliary Atresia. Launch of emerging therapies will significantly impact the Biliary Atresia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Atresia.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Biliary Atresia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Biliary Atresia Pipeline Analysis
  • Biliary Atresia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Biliary Atresia Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Biliary Atresia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Biliary Atresia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Biliary Atresia Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Biliary Atresia total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Biliary Atresiamarket Size during the forecast period (2017-2030)?
  • At what CAGR, the Biliary Atresia market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Biliary Atresia market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Biliary Atresia market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Biliary Atresia?
  • What is the historical Biliary Atresia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Biliary Atresia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia?
  • Out of all 7MM countries, which country would have the highest Incident population of Biliary Atresia during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Biliary Atresia?
  • What are the current treatment guidelines for the treatment of Biliary Atresia in the USA, Europe, and Japan?
  • What are the Biliary Atresia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Biliary Atresia?
  • How many therapies are develop by each company for the treatment of Biliary Atresia?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Biliary Atresia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Biliary Atresia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies develop to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Biliary Atresia and their status?
  • What are the key designations that have been granted for the emerging therapies for Biliary Atresia?
  • What are the global historical and forecasted market of Biliary Atresia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Biliary Atresia market,
  • To understand the future market competition in the Biliary Atresia market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia market.
  • To understand the future market competition in the Biliary Atresia market.

Table of Contents

1. Key Insights

2. Biliary Atresia: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Biliary Atresia in 2017
  • 2.2. Market Share (%) Distribution of Biliary Atresia in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Biliary Atresia

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Classification of Biliary Atresia
  • 5.4. Anatomical forms
  • 5.5. Clinical phenotypes of Biliary Atresia
  • 5.6. Kasai classification
  • 5.7. Etiology and Pathogenesis
  • 5.8. Pathogenesis
  • 5.9. Diagnosis
  • 5.10. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Incident Patient Population of Biliary Atresia
  • 6.3. United States
  • 6.4. Assumptions and Rationale
  • 6.5. Total Incident Cases of Biliary Atresia in the United States
  • 6.6. Type-specific Cases of Biliary Atresia in the United States
  • 6.7. Gender-specific Cases of Biliary Atresia in the United States
  • 6.8. EU-5
  • 6.9. Assumptions and Rationale
  • 6.10. Germany
  • 6.11. Total Incident Cases of Biliary Atresia in Germany
  • 6.12. Type-specific Cases of Biliary Atresia in Germany
  • 6.13. Gender-specific Cases of Biliary Atresia in Germany
  • 6.14. France
  • 6.15. Total Incident Cases of Biliary Atresia in France
  • 6.16. Type-specific Cases of Biliary Atresia in France
  • 6.17. Gender-specific Cases of Biliary Atresia in France
  • 6.18. Italy
  • 6.19. Total Incident Cases of Biliary Atresia in Italy
  • 6.20. Type-specific Cases of Biliary Atresia in Italy
  • 6.21. Gender-specific Cases of Biliary Atresia in Italy
  • 6.22. Spain
  • 6.23. Total Incident Cases of Biliary Atresia in Spain
  • 6.24. Type-specific Cases of Biliary Atresia in Spain
  • 6.25. Gender-specific Cases of Biliary Atresia in Spain
  • 6.26. UK
  • 6.27. Total Incident Cases of Biliary Atresia in the UK
  • 6.28. Type-specific Cases of Biliary Atresia in the UK
  • 6.29. Gender-specific Cases of Biliary Atresia in the UK
  • 6.30. Japan
  • 6.31. Assumptions and Rationale
  • 6.32. Total Incident Cases of Biliary Atresia in Japan
  • 6.33. Type-specific Cases of Biliary Atresia in Japan
  • 6.34. Gender-specific Cases of Biliary Atresia in Japan

7. Treatment and Management

  • 7.1. Surgical Management
  • 7.2. Liver Transplantation
  • 7.3. Medical management

8. Unmet needs

9. Emerging Therapies

  • 9.1. Key cross competition
  • 9.2. Odevixibat: Albireo
    • 9.2.1. Drug Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Clinical trial information
    • 9.2.5. Safety and Efficacy
    • 9.2.6. Product Profile
  • 9.3. Obeticholic Acid: Intercept Pharmaceuticals
    • 9.3.1. Drug Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Clinical Trial Information
    • 9.3.5. Product Profile

10. Biliary Atresia: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Biliary Atresia in 7MM
  • 10.3. Market Outlook
  • 10.4. United States Market Size
    • 10.4.1. The total market size of Biliary Atresia in the United States
    • 10.4.2. Therapy Based Market Size of Biliary Atresia in the United States
  • 10.5. Germany Market Size
    • 10.5.1. The total market size of Biliary Atresia in Germany
    • 10.5.2. Therapy Based Market Size of Biliary Atresia in Germany
  • 10.6. France Market Size
    • 10.6.1. The total market size of Biliary Atresia in France
    • 10.6.2. Therapy Based Market Size of Biliary Atresia in France
  • 10.7. Italy Market Size
    • 10.7.1. The total Market size of Biliary Atresia in the Italy
    • 10.7.2. Therapy Based Market Size of Biliary Atresia in Italy
  • 10.8. Spain Market Size
    • 10.8.1. The total market size of Biliary Atresia in Spain
    • 10.8.2. Therapy Based Market Size of Biliary Atresia in Spain
  • 10.9. UK Market Size
    • 10.9.1. The total market size of Biliary Atresia in the UK
    • 10.9.2. Therapy Based Market Size of Biliary Atresia in the UK
  • 10.10. Japan Market Size
    • 10.10.1. The total market size of Biliary Atresia in Japan
    • 10.10.2. Therapy Based Market Size of Biliary Atresia in Japan

11. Market Drivers

12. Market Barriers

13. SWOT Analysis

14. Case studies

  • 14.1. A Case of Biliary Atresia with Pancreaticobiliary Maljunction
  • 14.2. Case study: Biliary Atresia: A Case Report
  • 14.3. Case study: Clinical and Pathological Challenges in the Diagnosis of Late-Onset Biliary Atresia: Four Case Studies

15. KOL Views

16. Bibliography

17. Appendix

18. Report Methodology

  • 18.1. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1: Anatomical types of biliary atresia (BA)
  • Table 2: Clinical phenotypes of Biliary Atresia
  • Table 3: Total Incident Patient Population of Biliary Atresia in 7MM (2017-2030)
  • Table 4: Total Incident cases of Biliary Atresia in the United States (2017-2030)
  • Table 5: Type-specific cases of Biliary Atresia in the United States (2017-2030)
  • Table 6: Gender-specific cases of Biliary Atresia in the United States (2017-2030)
  • Table 7: Total Incident cases of Biliary Atresia in Germany (2017-2030)
  • Table 8: Type-specific cases of Biliary Atresia in Germany (2017-2030)
  • Table 9: Gender-specific cases of Biliary Atresia in Germany (2017-2030)
  • Table 10: Total Incident cases of Biliary Atresia in France (2017-2030)
  • Table 11: Type-specific cases of Biliary Atresia in France (2017-2030)
  • Table 12: Gender-specific cases of Biliary Atresia in the France (2017-2030)
  • Table 13: Total Incident cases of Biliary Atresia in Italy (2017-2030)
  • Table 14: Type-specific cases of Biliary Atresia in Italy (2017-2030)
  • Table 15: Gender-specific cases of Biliary Atresia in Italy (2017-2030)
  • Table 16: Total Incident cases of Biliary Atresia in Spain (2017-2030)
  • Table 17: Type-specific cases of Biliary Atresia in Spain (2017-2030)
  • Table 18: Gender-specific cases of Biliary Atresia in Spain (2017-2030)
  • Table 19: Total Incident cases of Biliary Atresia in the UK (2017-2030)
  • Table 20: Type-specific cases of Biliary Atresia in the UK (2017-2030)
  • Table 21: Gender-specific cases of Biliary Atresia in the UK (2017-2030)
  • Table 22: Total Incident cases of Biliary Atresia in Japan (2017-2030)
  • Table 23: Type-specific cases of Biliary Atresia in Japan (2017-2030)
  • Table 24: Gender-specific cases of Biliary Atresia in Japan (2017-2030)
  • Table 25: Key cross competition
  • Table 26: Key cross competition, Academics Trial
  • Table 27: Odevixibat, Clinical Trial Description, 2020
  • Table 28: Obeticholic acid, Clinical Trial Description, 2020
  • Table 29: 7 Major Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 30: United States Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 31: Therapy Based Market Size of Biliary Atresia in the US in USD Million (2017-2030)
  • Table 32: Germany Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 33: Therapy Based Market Size of Biliary Atresia in Germany in USD Million (2017-2030)
  • Table 34: France Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 35: Therapy Based Market Size of Biliary Atresia in France in USD Million (2017-2030)
  • Table 36: Italy Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 37: Therapy Based Market Size of Biliary Atresia in Italy in USD Million (2017-2030)
  • Table 38: Spain Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 39: Therapy Based Market Size of Biliary Atresia in Spain in USD Million (2017-2030)
  • Table 40: UK Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 41: Therapy Based Market Size of Biliary Atresia in the UK in USD Million (2017-2030)
  • Table 42: Japan Market Size of Biliary Atresia in USD Million (2017-2030)
  • Table 43:Therapy Based Market Size of Biliary Atresia in Japan in USD Million (2017-2030)

List of Figures

  • Figure 1: Signs and Symptoms
  • Figure 2: Clincal Phenotypes of BA
  • Figure 3: Classification of biliary atresia according to Kasai classification system
  • Figure 4: Schematic of the hypothesis of biliary atresia etiology
  • Figure 5: Etiology and Pathogenesis
  • Figure 6: Innate immune receptors present in Cholangiocytes
  • Figure 7: Mechanism of obstruction in biliary atresia
  • Figure 8: Disease progression mechanisms after bile duct obstruction
  • Figure 9: Total Incident Patient Population of Biliary Atresia in 7MM (2017-2030)
  • Figure 10: Total Incident cases of Biliary Atresia in the United States (2017-2030)
  • Figure 11: Type-specific cases of Biliary Atresia in the US (2017-2030)
  • Figure 12: Gender-specific cases of Biliary Atresia in the United States (2017-2030)
  • Figure 13: Total Incident cases of Biliary Atresia in Germany (2017-2030)
  • Figure 14: Type-specific cases of Biliary Atresia in the Germany 2017-2030)
  • Figure 15: Gender-specific cases of Biliary Atresia in Germany (2017-2030)
  • Figure 16: Total Incident cases of Biliary Atresia in France (2017-2030)
  • Figure 17: Type-specific cases of Biliary Atresia in the France 2017-2030)
  • Figure 18: Gender-specific cases of Biliary Atresia in France (2017-2030)
  • Figure 19: Total Incident cases of Biliary Atresia in Italy (2017-2030)
  • Figure 20: Type-specific cases of Biliary Atresia in the Italy 2017-2030)
  • Figure 21: Gender-specific cases of Biliary Atresia in Italy (2017-2030)
  • Figure 22: Total Incident cases of Biliary Atresia in Spain (2017-2030)
  • Figure 23: Type-specific cases of Biliary Atresia in the Spain 2017-2030)
  • Figure 24: Gender-specific cases of Biliary Atresia in Spain (2017-2030)
  • Figure 25: Total Incident cases of Biliary Atresia in the UK (2017-2030)
  • Figure 26: Type-specific cases of Biliary Atresia in the UK 2017-2030)
  • Figure 27: Gender-specific cases of Biliary Atresia in the UK (2017-2030)
  • Figure 28: Total Incident cases of Biliary Atresia in Japan (2017-2030)
  • Figure 29: Type-specific cases of Biliary Atresia in the Japan 2017-2030)
  • Figure 30: Gender-specific cases of Biliary Atresia in Japan (2017-2030)
  • Figure 31: Management of children with Biliary Atresia.
  • Figure 32: Unmet Needs of Biliary Atresia
  • Figure 33: 7 Major Market Size of Biliary Atresia in USD Million (2017-2030)
  • Figure 34: Market Size of Biliary Atresia in the United States, USD Millions (2017-2030)
  • Figure 35: Therapy Based Market Size of Biliary Atresia in the US in USD Million (2017-2030)
  • Figure 36: Market Size of Biliary Atresia in Germany, USD Millions (2017-2030)
  • Figure 37: Therapy Based Market Size of Biliary Atresia in Germany in USD Million (2017-2030)
  • Figure 38: Market Size of Biliary Atresia in France, USD Millions (2017-2030)
  • Figure 39: Therapy Based Market Size of Biliary Atresia in France in USD Million (2017-2030)
  • Figure 40: Market Size of Biliary Atresia in Italy, USD Millions (2017-2030)
  • Figure 41: Therapy Based Market Size of Biliary Atresia in Italy in USD Million (2017-2030)
  • Figure 42: Market Size of Biliary Atresia in Spain, USD Millions (2017-2030)
  • Figure 43: Therapy Based Market Size of Biliary Atresia in Spain in USD Million (2017-2030)
  • Figure 44: Market Size of Biliary Atresia in the UK, USD Millions (2017-2030)
  • Figure 45: Therapy Based Market Size of Biliary Atresia in the UK in USD Million (2017-2030)
  • Figure 46: Market Size of Biliary Atresia in Japan, USD Millions (2017-2030)
  • Figure 47:Therapy Based Market Size of Biliary Atresia in Japan in USD Million (2017-2030)
  • Figure 48: Market Drivers
  • Figure 49: Market Barriers